MA55821A - Antagonistes 5-ht2a destinés à être utilisés dans le traitement de la dépression - Google Patents
Antagonistes 5-ht2a destinés à être utilisés dans le traitement de la dépressionInfo
- Publication number
- MA55821A MA55821A MA055821A MA55821A MA55821A MA 55821 A MA55821 A MA 55821A MA 055821 A MA055821 A MA 055821A MA 55821 A MA55821 A MA 55821A MA 55821 A MA55821 A MA 55821A
- Authority
- MA
- Morocco
- Prior art keywords
- depression
- treatment
- ht2a antagonists
- ht2a
- antagonists
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/452—Piperidinium derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- External Artificial Organs (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19207578 | 2019-11-07 | ||
| PCT/EP2020/081357 WO2021089824A1 (fr) | 2019-11-07 | 2020-11-06 | Antagonistes 5-ht2a destinés à être utilisés dans le traitement de la dépression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA55821A true MA55821A (fr) | 2022-05-04 |
| MA55821B1 MA55821B1 (fr) | 2023-08-31 |
Family
ID=68502828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA55821A MA55821B1 (fr) | 2019-11-07 | 2020-11-06 | Antagonistes 5-ht2a destinés à être utilisés dans le traitement de la dépression |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US11246860B2 (fr) |
| EP (1) | EP3962601B1 (fr) |
| JP (1) | JP7566021B2 (fr) |
| CN (1) | CN114761083B (fr) |
| AU (1) | AU2020379225B2 (fr) |
| BR (1) | BR112022008037A2 (fr) |
| CA (1) | CA3156513A1 (fr) |
| DK (1) | DK3962601T3 (fr) |
| ES (1) | ES2953926T3 (fr) |
| FI (1) | FI3962601T3 (fr) |
| HR (1) | HRP20230856T1 (fr) |
| HU (1) | HUE062369T2 (fr) |
| IL (1) | IL292585B2 (fr) |
| LT (1) | LT3962601T (fr) |
| MA (1) | MA55821B1 (fr) |
| MD (1) | MD3962601T2 (fr) |
| PL (1) | PL3962601T3 (fr) |
| PT (1) | PT3962601T (fr) |
| SI (1) | SI3962601T1 (fr) |
| WO (1) | WO2021089824A1 (fr) |
| ZA (1) | ZA202204809B (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11246860B2 (en) * | 2019-11-07 | 2022-02-15 | Lophora ApS | 5-HT2A agonists for use in treatment of depression |
| US12240813B2 (en) | 2020-05-19 | 2025-03-04 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| AU2021328671A1 (en) | 2020-08-18 | 2023-02-16 | Cybin Irl Limited | Phenethylamine derivatives, compositions, and methods of use |
| EP4329759A4 (fr) | 2021-04-30 | 2025-07-16 | Mind Medicine Inc | Formes cristallines de sels de lsd |
| WO2022234010A1 (fr) * | 2021-05-06 | 2022-11-10 | Lophora ApS | Sels d'addition d'acide de (s)-3-(2,5-diméthoxy-4-(trifluorométhyl)phényl)pipéridine et de (s)-3-(2-méthoxy-5-(méthylthio)-4-(trifluorométhyl)phényl)pipéridine, leurs polymorphes spécifiques et leurs procédés de fabrication |
| IL309842A (en) * | 2021-07-26 | 2024-02-01 | Univ Louisiana State | Compounds and methods for treating situations where the response depends on 5-HT2 |
| JP7846211B2 (ja) | 2021-08-19 | 2026-04-14 | デフィニウム セラピューティクス ユーエス， インコーポレイテッド | 治療適用のためのｄ－リゼルグ酸ジエチルアミドの即時放出製剤 |
| WO2024181024A1 (fr) * | 2023-03-02 | 2024-09-06 | 本田技研工業株式会社 | Composition |
| WO2025008804A1 (fr) * | 2023-07-06 | 2025-01-09 | M – Path Biopharma Ltd. | Polythérapie pour apporter des améliorations aux effets secondaires d'un traitement par inhibiteurs des récepteurs des œstrogènes |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2413878A1 (fr) * | 2000-06-20 | 2001-12-27 | Atherogenics, Inc. | 1,3-bis-(phenyl substitue)-2-propene-1-ones et leur utilisation dans le traitement des troubles vehicules par vcam-1 |
| GB201314286D0 (en) * | 2013-08-08 | 2013-09-25 | Takeda Pharmaceutical | Therapeutic Compounds |
| US11246860B2 (en) * | 2019-11-07 | 2022-02-15 | Lophora ApS | 5-HT2A agonists for use in treatment of depression |
-
2020
- 2020-11-05 US US17/090,457 patent/US11246860B2/en active Active
- 2020-11-06 LT LTEPPCT/EP2020/081357T patent/LT3962601T/lt unknown
- 2020-11-06 BR BR112022008037A patent/BR112022008037A2/pt unknown
- 2020-11-06 CA CA3156513A patent/CA3156513A1/fr active Pending
- 2020-11-06 JP JP2022525596A patent/JP7566021B2/ja active Active
- 2020-11-06 EP EP20808308.9A patent/EP3962601B1/fr active Active
- 2020-11-06 WO PCT/EP2020/081357 patent/WO2021089824A1/fr not_active Ceased
- 2020-11-06 ES ES20808308T patent/ES2953926T3/es active Active
- 2020-11-06 HU HUE20808308A patent/HUE062369T2/hu unknown
- 2020-11-06 DK DK20808308.9T patent/DK3962601T3/da active
- 2020-11-06 HR HRP20230856TT patent/HRP20230856T1/hr unknown
- 2020-11-06 PL PL20808308.9T patent/PL3962601T3/pl unknown
- 2020-11-06 CN CN202080078033.1A patent/CN114761083B/zh active Active
- 2020-11-06 PT PT208083089T patent/PT3962601T/pt unknown
- 2020-11-06 FI FIEP20808308.9T patent/FI3962601T3/fi active
- 2020-11-06 SI SI202030239T patent/SI3962601T1/sl unknown
- 2020-11-06 MD MDE20220277T patent/MD3962601T2/ro unknown
- 2020-11-06 AU AU2020379225A patent/AU2020379225B2/en active Active
- 2020-11-06 IL IL292585A patent/IL292585B2/en unknown
- 2020-11-06 MA MA55821A patent/MA55821B1/fr unknown
-
2021
- 2021-06-16 US US17/349,255 patent/US11633390B2/en active Active
- 2021-07-06 US US17/368,351 patent/US11642336B2/en active Active
-
2022
- 2022-04-29 ZA ZA2022/04809A patent/ZA202204809B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021089824A1 (fr) | 2021-05-14 |
| DK3962601T3 (da) | 2023-09-04 |
| CN114761083B (zh) | 2024-02-13 |
| IL292585B1 (en) | 2023-04-01 |
| SI3962601T1 (sl) | 2023-10-30 |
| PL3962601T3 (pl) | 2023-10-09 |
| MD3962601T2 (ro) | 2023-10-31 |
| AU2020379225A1 (en) | 2022-05-26 |
| PT3962601T (pt) | 2023-08-28 |
| FI3962601T3 (fi) | 2023-08-09 |
| US11633390B2 (en) | 2023-04-25 |
| MA55821B1 (fr) | 2023-08-31 |
| HUE062369T2 (hu) | 2023-10-28 |
| US11246860B2 (en) | 2022-02-15 |
| US20220062257A1 (en) | 2022-03-03 |
| ES2953926T3 (es) | 2023-11-17 |
| CA3156513A1 (fr) | 2021-05-14 |
| JP7566021B2 (ja) | 2024-10-11 |
| LT3962601T (lt) | 2023-09-11 |
| ZA202204809B (en) | 2022-11-30 |
| EP3962601B1 (fr) | 2023-05-31 |
| HRP20230856T1 (hr) | 2023-11-10 |
| AU2020379225B2 (en) | 2026-03-26 |
| IL292585A (en) | 2022-06-01 |
| US20210330658A1 (en) | 2021-10-28 |
| IL292585B2 (en) | 2023-08-01 |
| BR112022008037A2 (pt) | 2022-07-12 |
| JP2023501275A (ja) | 2023-01-18 |
| CN114761083A (zh) | 2022-07-15 |
| US20210137908A1 (en) | 2021-05-13 |
| EP3962601A1 (fr) | 2022-03-09 |
| US11642336B2 (en) | 2023-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA55821A (fr) | Antagonistes 5-ht2a destinés à être utilisés dans le traitement de la dépression | |
| EP3908270A4 (fr) | Combinaison de dextrométhorphane et de bupropion pour le traitement de la dépression | |
| MA49458A (fr) | Composés interagissant avec la superfamille ras destinés à être utilisés dans le traitement de cancers, de maladies inflammatoires, de rasopathies et de maladies fibrotiques | |
| MA51032A (fr) | Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée | |
| FR24C1010I2 (fr) | Modulateurs des récepteurs p2x3 et p2x2/3 de diaminopyrimidine destinés à être utilisés dans le traitement de la toux | |
| MA49760A (fr) | Mavacamten destiné à être utilisé dans le traitement de la cardiomyopathie hypertrophique | |
| MA47688A (fr) | Compositions utiles dans le traitement de l'amyotrophie spinale | |
| MA54515A (fr) | Dérivés de quinoléine destinés à être utilisés dans le traitement de maladies inflammatoires | |
| EP3267995A4 (fr) | Inhibiteurs de l'activité de la déshydrogénase à chaîne courte pour le traitement de la fibrose | |
| MA50905A (fr) | Composés et compositions pharmaceutiques de ceux-ci destinés à être utilisés dans le traitement de maladies fibrotiques | |
| PL3972643T3 (pl) | Antagoniści układu dopełniacza do stosowania w sposobach leczenia neuropatii paraproteinemicznych | |
| EP3328864A4 (fr) | Composés et compositions thérapeutiques pour le traitement de troubles sociaux et de troubles liés à la toxicomanie | |
| EP3463341A4 (fr) | Immunomodulateurs à base d'aminocylindazole pour le traitement de maladies auto-immunes | |
| EP3645120A4 (fr) | Compositions d'antagoniste de nk-1 et méthodes destinées à être utilisées dans le traitement de la dépression | |
| MA50233A (fr) | Mic-1 et glp-1 destinés à être utilisés dans le traitement de l'obésité | |
| MA55218A (fr) | Eskétamine pour le traitement de la dépression | |
| MA49131A (fr) | Utilisation d'antagonistes de klk5 pour le traitement d'une maladie | |
| MA53280A (fr) | Composés utiles dans la thérapie du vih | |
| MA47111A (fr) | Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancer | |
| EP3426287A4 (fr) | Méthodes et kits destinés à être utilisés pour la prévention et le traitement de la candidose vulvo-vaginale | |
| MA43825A (fr) | Schémas posologiques pour le traitement d'infections fongiques | |
| MA43861A (fr) | Inhibiteurs il-8 destinés à être utilisés dans le traitement d'une neuropathie périphérique induite par une chimiothérapie | |
| EP3442538A4 (fr) | Traitement de syndrome extrapyramidal à l'aide de trapidil | |
| IL289371A (en) | Methylthioninium for use in the treatment of synaptopathies | |
| EP3813870C0 (fr) | Inhibiteur de ccr5 destiné à être utilisé dans le traitement du cancer |